Clinical trials: Chest Pains
Coronary Artery Diseases
BIOTRONIK - BIOFLOW-III Registry French Satellite
For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success.
- Trial name
- NCT02273648
- Testing
- Drug Eluting Stent (DES)
- Where
- 50 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Biotronik France
Hypercholesterolemia, Myocardial Infarction
IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
This is a randomized, active-control, double-blind study of subjects with stabilized high-risk acute coronary syndrome (ACS). The primary objective is to evaluate the clinical benefit of Ezetimibe/Simvastatin Combination 10/40…
- Trial name
- NCT00202878
- Testing
- ezetimibe/simvastatin, simvastatin
- Volunteers
- 18,144 people
- Sponsor
- Organon and Co
Angina, Hypertension
To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg
To demonstrate the relative bioavailability of atenolol tablets, 100 mg.
- Trial name
- NCT00946725
- Testing
- Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical), Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sandoz
Post Acute Coronary Syndrome, Myocardial Ischemia
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular…
- Trial name
- NCT00409578
- Testing
- Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 1,101 people
- Sponsor
- Novartis
Coronary Artery Disease, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
First-in-Human Study Using the SiroMax™ Sirolimus-Coated Balloon Catheter as a Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter to Treat Subjects Who Have Coronary Artery Disease (CAD) Involving In-Stent Restenosis (ISR) or an Unstented Lesion in a Small Coronary Vessel (DNSV).
The goal of this clinical trial is to learn if the SiroMax™ drug-coated balloon catheter is safe and works to treat stenotic coronary lesions in adults.
- Conditions
- Coronary Artery Disease, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), In-Stent Restenosis or De Novo Coronary Artery Lesions, In-Stent Stenosis (Restenosis) of Coronary Artery Stent
- Trial name
- SMART-I (NCT07811024)
- Testing
- Sirolimus-coated balloon catheter
- Where
- 2 sites in Uzbekistan
- Volunteers
- 60 people
- Sponsor
- Tonic Medical, Inc.
Refractory Angina
Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina
Therapeutic neovascularization is an innovative strategy for cardiac tissue recovery due to chronic, intense ischemia. Thus stem cell therapy has become a promising procedure for the large number of patients with refractory…
- Trial name
- ReACT (NCT01966042)
- Testing
- Local sedation, Bone Marrow Aspiration, Minithoracotomy
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- CellPraxis Bioengenharia Ltda.
Unstable Angina, Myocardial Infarction
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention [PCI]…
- Conditions
- Unstable Angina, Myocardial Infarction, Acute Disease
- Trial name
- NCT00093158
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 13,800 people
- Sponsor
- The Medicines Company
Coronary Artery Disease, Angina Pectoris
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
The PREDICT study is to develop and validate a diagnostic blood ASGES (age, sex, gene expression score) or Corus CAD for atherosclerotic coronary artery disease (CAD).
- Conditions
- Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases
- Trial name
- PREDICT (NCT00500617)
- Testing
- Corus CAD (ASGES)
- Where
- 10 sites in United States
- Volunteers
- 4,350 people
- Sponsor
- CardioDx
Refractory Angina, Coronary Artery Disease
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
This is a two-part study, comprised of an initial open-label run-in phase (Part 1) in a subset of 3 subjects to provide first data regarding safety, and feasibility of the percutaneous endovascular catheter-facilitated…
- Trial name
- EXACT2 (NCT07048808)
- Testing
- XC001
- Where
- 14 sites in United States
- Volunteers
- 106 people
- Sponsor
- XyloCor Therapeutics, Inc.
Chronic Stable Angina
Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule
This study is designed to evaluate dose-proportionality of Dilatrend SR 8mg, 16mg, 32mg, 64mg, 128mg in healthy male volunteers.
- Trial name
- NCT01369472
- Testing
- Dilatrend SR capsule
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Stable Angina
Efficacy and Safety of Monocordil Manufactured by Laboratórios Baldacci
Phase III clinical study for the evaluation of clinic and cardiologic effects of isosorbide mononitrate from the incidence of events (angina episodes). This is an open, comparative, monocentric trial.
- Trial name
- NCT02152579
- Testing
- Isosorbide-5-mononitrate
- Where
- Brazil
- Volunteers
- 86 people
- Sponsor
- Laboratórios Baldacci S.A
Angina Exacerbation Acute
Effects of Low Frequency Magnetic Field on Exercise Induced Angina
The investigators have previously shown that a frequency of 15.95-16.00 Hz protects against acute myocardial infarction in rats.
- Trial name
- NCT01423422
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Aerotel Ltd
Refractory Angina Pectoris
Extracorporeal Shockwave Therapy for the Treatment of Refractory Angina Pectoris
Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones. The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with…
- Trial name
- NCT00662727
- Testing
- Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Medispec
Stable Angina, Unstable Angina
Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease
To evaluate the safety and effectiveness of the ALEX stent in a real-world setting of percutaneous coronary interventions in patients with coronary heart disease.
- Conditions
- Stable Angina, Unstable Angina, Myocardial Infarction
- Trial name
- ALEX OCT (NCT01637012)
- Testing
- Implantation
- Where
- 5 sites in Poland
- Volunteers
- 60 people
- Sponsor
- Balton Sp.zo.o.
Stable Angina, Coronary Disease
Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
This study of 402 cases of stable angina subjects who were diagnosed as Coronary Heart Disease (CHD) is a randomized, blank controlled, multi-center clinical study.
- Trial name
- SIGMART (NCT01396395)
- Testing
- Nicorandil, Standard Treatment
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Acute Coronary Syndrome
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).
- Trial name
- NCT00677053
- Testing
- TAK-442
- Where
- 103 sites in United States, Argentina and 17 more
- Volunteers
- 2,753 people
- Sponsor
- Takeda
Refractory Angina
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
The objectives of the study are to assess the safety, tolerability, and potential efficacy of IMB-1018972 on patients with refractory angina.
- Trial name
- NCT04306237
- Testing
- IMB-1018972
- Where
- United States
- Sponsor
- Imbria Pharmaceuticals, Inc.
Acute Coronary Syndrome
Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina
The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.
- Trial name
- NCT00353067
- Testing
- veliflapon (DG-031)
- Where
- 11 sites in United States
- Volunteers
- 3,450 people
- Sponsor
- deCODE genetics
Coronary Artery Disease, Angina Pectoris
Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound
The purpose of this study is to verify whether additional administration of Alirocumab exerts a stronger stabilizing effect on the vulnerable plaque in CAD, compared with statin alone administration in patients receiving PCI.
- Trial name
- ANTARES (NCT03529253)
- Testing
- Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily, Rosuvastatin calcium10mg
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Kobe University
Angina Pectoris
A Prospective, Single-arm, Multi-centre, Observational, Real World Registry
A prospective, single-arm, multi-centre, observational, real world registry to evaluate safety and performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System for very long coronary lesions.
- Trial name
- Morpheus (NCT02901353)
- Testing
- Sirolimus Eluting Coronary Stent System
- Where
- 5 sites in Hungary, Jordan and 2 more
- Volunteers
- 400 people
- Sponsor
- Meril Life Sciences Pvt. Ltd.